After posting an impressive 50% revenue growth in the second quarter, driven by strong patient demand across all three of its core products, this company has confidently raised its full-year revenue guidance. With an upwardly revised full-year guidance and a solid track record of execution, the company is drawing increased investor attention, offering a compelling reason to revisit its stock.
The company we are profiling today is Xeris Biopharma Holdings Inc. (XERS), whose stock touched a new 52-week high of $8.51 last week.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com